Faron Pharmaceuticals
0.48 EUR
-0.62 %
5,705 following
Corporate customer
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
Valuation
Income statement
Quarterly estimates
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Faron Pharmaceuticals
Dividend yield
Median 2021-2025
P/B
Median 2021-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 3.30 | 2.91 | 3.24 | 3.71 | 3.77 | 2.24 | 2.45 | 0.48 | 0.48 | 0.48 | 0.48 |
| Shares | 43.3 | 46.9 | 53.2 | 59.8 | 68.8 | 104.6 | 118.6 | 222.8 | 246.1 | 265.5 | 265.5 |
| Market cap | 142.9 | 136.5 | 172.5 | 221.6 | 259.3 | 234.4 | 290.5 | 107.6 | 118.9 | 128.2 | 128.2 |
| Enterprise value | 138.2 | 135.1 | 169.0 | 227.5 | 265.3 | 236.7 | 302.6 | 102.4 | 130.4 | 156.2 | 168.4 |
| EV/S | 34,556.0 | 33,775.4 | 42,241.4 | 56,880.5 | 66,337.2 | 59,166.2 | 75,657.0 | 25,596.0 | 32,609.6 | 39,043.1 | 159.9 |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT (adj.) | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E (adj.) | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 88.7 | neg. | 58.8 | neg. | neg. | neg. | neg. | 83.8 | neg. | neg. | neg. |
| P/S | 35,714.3 | 34,117.3 | 43,117.9 | 55,389.8 | 64,831.5 | 58,589.4 | 72,618.0 | 26,905.5 | 29,721.4 | 32,054.3 | 121.8 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 15.8 % | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -78.0 % | -107.8 % | 3.3 % | -133.4 % | -523.3 % | -615.2 % |
| Gearing ratio | -287.8 % | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -23.6 % | -65.7 % | -407.9 % | -73.5 % | -86.6 % | -85.4 % |